litlas
Log inCreate account

Nicholas C. Turner

Active 1989–2025

181
Papers
42,345
Citations
89
h-index
169
i10-index

Citations

Citations per year for Nicholas C. Turner1964: 4 citations1971: 1 citations1990: 8 citations1991: 4 citations1992: 13 citations1993: 6 citations1994: 3 citations1995: 10 citations1996: 6 citations1997: 9 citations1998: 9 citations1999: 6 citations2000: 8 citations2001: 12 citations2002: 10 citations2003: 7 citations2004: 9 citations2005: 15 citations2006: 38 citations2007: 75 citations2008: 129 citations2009: 130 citations2010: 263 citations2011: 223 citations2012: 227 citations2013: 265 citations2014: 214 citations2015: 279 citations2016: 387 citations2017: 489 citations2018: 513 citations2019: 1,738 citations2020: 2,018 citations2021: 2,137 citations2022: 1,901 citations2023: 1,649 citations2024: 2,505 citations2025: 1,543 citations2026: 45 citations1965–1970: no citations, so these years are not shown1972–1989: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 4,388 citing papers, 23.4% of this breakdownChina: 2,182 citing papers, 11.7% of this breakdownUnited Kingdom: 1,524 citing papers, 8.1% of this breakdownItaly: 1,202 citing papers, 6.4% of this breakdownGermany: 871 citing papers, 4.7% of this breakdownFrance: 783 citing papers, 4.2% of this breakdownSpain: 717 citing papers, 3.8% of this breakdownCanada: 607 citing papers, 3.2% of this breakdownJapan: 524 citing papers, 2.8% of this breakdownAustralia: 510 citing papers, 2.7% of this breakdownNetherlands: 466 citing papers, 2.5% of this breakdownSouth Korea: 382 citing papers, 2% of this breakdown
0%23.4%Other 24.5%

Institutions

Fields

  • Medicine49.6%
  • Biochemistry, Genetics and Molecular Biology45.6%
  • Computer Science1.1%
  • Immunology and Microbiology0.9%
  • Engineering0.7%
  • Chemistry0.5%
  • Other1.6%

Topics

  • Advanced Breast Cancer Therapies7.3%
  • Cancer Genomics and Diagnostics6.9%
  • Cancer-related Molecular Pathways4.4%
  • Breast Cancer Treatment Studies3.8%
  • HER2/EGFR in Cancer Research3.6%
  • PARP inhibition in cancer therapy3.6%
  • Other70.4%

Coauthors

All papers

Open in search
  1. ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer

    Authors: Alessandra Gennari, Fabrice André, Carlos H. Barrios, Javier Cortés, Evandro de Azambuja, A. DeMichele, Rebecca Dent, Deborah Fenlon, Joseph Gligorov, Sara A. Hurvitz, Seock‐Ah Im, David Krug, Wolfgang G. Kunz, Sherene Loi, Frédérique Penault‐Llorca, Jens Ricke, Mark E. Robson, Hope S. Rugo, Cristina Saura, Peter Schmid, Christian F. Singer, Tanja Španić, Sara M. Tolaney, Nicholas C. Turner, Giuseppe Curigliano, Sibylle Loibl, Shani Paluch–Shimon, Nadia Harbeck - Annals of Oncology 2021 cited by 1,367

  2. Capivasertib in Hormone Receptor–Positive Advanced Breast Cancer

    Authors: Nicholas C. Turner, Mafalda Oliveira, Sacha J. Howell, Florence Dalenc, Javier Cortés, Henry Gómez, Xichun Hu, Komal Jhaveri, Petr Krivorotko, Sibylle Loibl, Serafin Morales Murillo, Meena Okera, Yeon Hee Park, Joohyuk Sohn, Masakazu Toi, Eriko Tokunaga, Samih Yousef, Lyudmila Zhukova, Elza C. de Bruin, Lynda Grinsted, Gaia Schiavon, Andrew Foxley, Hope S. Rugo - New England Journal of Medicine 2023 cited by 704

  3. ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group

    Authors: Javier Pascual, Gerhardt Attard, François‐Clément Bidard, Giuseppe Curigliano, Leticia De Mattos‐Arruda, Maximilian Diehn, Antoîne Italiano, Johan Lindberg, Jason D. Merker, Clara Montagut, Nicola Normanno, Klaus Pantel, George Pentheroudakis, Sanjay Popat, Jorge S. Reis‐Filho, Jeanne Tie, Joan Seoane, N. Tarazona, Takayuki Yoshino, Nicholas C. Turner - Annals of Oncology 2022 cited by 664

  4. The history and future of targeting cyclin-dependent kinases in cancer therapy

    Authors: Uzma Asghar, Agnieszka K. Witkiewicz, Nicholas C. Turner, Erik S. Knudsen - Nature Reviews Drug Discovery 2015 cited by 1,762

  5. Fibroblast growth factor signalling: from development to cancer

    Authors: Nicholas C. Turner, Richard Grose - Nature reviews. Cancer 2010 cited by 2,674

  6. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial

    Authors: Massimo Cristofanilli, Nicholas C. Turner, Igor Bondarenko, Jungsil Ro, Seock‐Ah Im, Norikazu Masuda, Marco Colleoni, Angela DeMichele, Sherene Loi, Sunil Verma, Hiroji Iwata, Nadia Harbeck, Ke Zhang, Kathy Puyana Theall, Yuqiu Jiang, Cynthia Huang Bartlett, María Koehler, Dennis J. Slamon - The Lancet Oncology 2016 cited by 1,822

  7. Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer

    Authors: Nicholas C. Turner, Dennis J. Slamon, Jungsil Ro, Igor Bondarenko, Seock‐Ah Im, Norikazu Masuda, Marco Colleoni, Angela DeMichele, Sherene Loi, Sunil Verma, Hiroji Iwata, Nadia Harbeck, Sibylle Loibl, Fabrice André, Kathy Puyana Theall, Xin Huang, C. Giorgetti, Cynthia Huang Bartlett, Massimo Cristofanilli - New England Journal of Medicine 2018 cited by 1,293

  8. Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer

    Authors: Nicholas C. Turner, Jungsil Ro, Fabrice André, Sherene Loi, Sunil Verma, Hiroji Iwata, Nadia Harbeck, Sibylle Loibl, Cynthia Huang Bartlett, Ke Zhang, C. Giorgetti, Sophia Randolph, María Koehler, Massimo Cristofanilli - New England Journal of Medicine 2015 cited by 1,586

  9. Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor–Positive Breast Cancer

    Authors: María Teresa Herrera-Abreu, Marta Palafox, Uzma Asghar, Martín A. Rivas, Rosalind Cutts, Isaac García-Murillas, Alex Pearson, Marta Guzmán, Olga Rodríguez, Judit Grueso, Meritxell Bellet, Javier Cortés, Richard Elliott, Sunil Pancholi, Christopher J. Lord, José Baselga, Mitch Dowsett, Lesley‐Ann Martin, Nicholas C. Turner, Violeta Serra - Cancer Research 2016 cited by 779

  10. Treating cancer with selective CDK4/6 inhibitors

    Authors: Ben O’Leary, Richard S. Finn, Nicholas C. Turner - Nature Reviews Clinical Oncology 2016 cited by 1,157

  11. Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer

    Authors: Isaac García-Murillas, Gaia Schiavon, Britta Weigelt, Charlotte K.Y. Ng, Sarah Hrebien, Rosalind Cutts, Maggie C.U. Cheang, Peter Osin, Ashutosh Nerurkar, Iwanka Kozarewa, Javier Armisen Garrido, Mitch Dowsett, Jorge S. Reis‐Filho, Ian E. Smith, Nicholas C. Turner - Science Translational Medicine 2015 cited by 1,132

  12. The Genetic Landscape and Clonal Evolution of Breast Cancer Resistance to Palbociclib plus Fulvestrant in the PALOMA-3 Trial

    Authors: Ben O’Leary, Rosalind Cutts, Yuan Liu, Sarah Hrebien, Xin Huang, Kerry Fenwick, Fabrice André, Sibylle Loibl, Sherene Loi, Isaac García-Murillas, Massimo Cristofanilli, Cynthia Huang Bartlett, Nicholas C. Turner - Cancer Discovery 2018 cited by 667

  13. Advances and challenges in targeting FGFR signalling in cancer

    Authors: Irina S. Babina, Nicholas C. Turner - Nature reviews. Cancer 2017 cited by 796

  14. Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study

    Authors: Hope S. Rugo, Florence Lerebours, Eva Ciruelos, Pamela Drullinsky, Manuel Ruíz‐Borrego, Patrick Neven, Yeon Hee Park, Aleix Prat, Thomas Bachelot, Dejan Juric, Nicholas C. Turner, Nickolas A. Sophos, Juan Pablo Zarate, Christina Arce, Yu-Ming Shen, Stuart Turner, Hemanth Kanakamedala, Wei‐Chun Hsu, Stephen Chia - The Lancet Oncology 2021 cited by 349

  15. Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial

    Authors: Eric P. Winer, Oleg Lipatov, Seock‐Ah Im, Anthony Gonçalvès, Eva Muñoz‐Couselo, Keun Seok Lee, Peter Schmid, Kenji Tamura, Laura Testa, Isabell Witzel, Shoichiro Ohtani, Nicholas C. Turner, Stefania Zambelli, Nadia Harbeck, Fabrice André, Rebecca Dent, Xuan Zhou, Vassiliki Karantza, Jaime Mejia, Javier Cortés - The Lancet Oncology 2021 cited by 493

  16. Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review

    Authors: Jason D. Merker, Geoffrey R. Oxnard, Carolyn C. Compton, Maximilian Diehn, Patricia A. Hurley, Alexander J. Lazar, Neal Lindeman, Christina M. Lockwood, Alex J. Rai, Richard L. Schilsky, Apostolia M. Tsimberidou, Patricia Vasalos, Brooke L. Billman, Thomas K. Oliver, Suanna S. Bruinooge, Daniel F. Hayes, Nicholas C. Turner - Archives of Pathology & Laboratory Medicine 2018 cited by 929

  17. Assessment of Molecular Relapse Detection in Early-Stage Breast Cancer

    Authors: Isaac García-Murillas, Neha Chopra, Iñaki Comino‐Méndez, Matthew Beaney, Holly Tovey, Rosalind Cutts, Claire Swift, Divya Kriplani, Maria Afentakis, Sarah Hrebien, Giselle Walsh-Crestani, Peter Barry, Stephen Johnston, Alistair Ring, Judith M. Bliss, Simon Russell, Abigail Evans, Anthony Skene, Duncan Wheatley, Mitch Dowsett, Ian E. Smith, Nicholas C. Turner - JAMA Oncology 2019 cited by 428

  18. Results of the c-TRAK TN trial: a clinical trial utilising ctDNA mutation tracking to detect molecular residual disease and trigger intervention in patients with moderate- and high-risk early-stage triple-negative breast cancer

    Authors: Nicholas C. Turner, Claire Swift, Ben Jenkins, Lucy Kilburn, Maria Coakley, Matthew Beaney, Lisa Fox, Kate Goddard, Isaac García-Murillas, Paula Proszek, Peter S Hall, Catherine Harper‐Wynne, Tamas Hickish, Sarah Kernaghan, Iain R. Macpherson, Alicia Okines, Carlo Palmieri, Sophie Perry, Kat Randle, Claire Snowdon, Hilary Stobart, Andrew Wardley, Duncan Wheatley, Simon Waters, Matthew Winter, Michael Hubank, Steven Allen, Judith M. Bliss, Shing Leng Chan, Anne Armstrong, F. Raja, Peter Schmid, Andrew Tutt, René L. Roux, Susan Cleator - Annals of Oncology 2022 cited by 191

  19. Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial

    Authors: Peter Schmid, Jacinta Abraham, Stephen Chan, Duncan Wheatley, Adrian Murray Brunt, Gia Nemsadze, Richard D. Baird, Yeon Hee Park, Peter S Hall, Timothy Perren, Robert C. Stein, László Mangel, Jean-­Marc Ferrero, Melissa Phillips, John Conibear, Javier Cortés, Andrew Foxley, Elza C. de Bruin, Robert McEwen, Daniel Stetson, Brian Dougherty, Shah‐Jalal Sarker, Aaron Prendergast, Max McLaughlin-Callan, Matthew Burgess, Cheryl Lawrence, Hayley Cartwright, Kelly Mousa, Nicholas C. Turner - Journal of Clinical Oncology 2019 cited by 389

  20. The CDK4/6 inhibitor revolution — a game-changing era for breast cancer treatment

    Authors: Laura Morrison, Sibylle Loibl, Nicholas C. Turner - Nature Reviews Clinical Oncology 2023 cited by 246

  21. Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future

    Authors: Laura M. Spring, Seth A. Wander, Fabrice André, Beverly Moy, Nicholas C. Turner, Aditya Bardia - The Lancet 2020 cited by 466

  22. Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial

    Authors: Nicholas C. Turner, Belinda Kingston, Lucy Kilburn, Sarah Kernaghan, Andrew Wardley, Iain R. Macpherson, Richard D. Baird, Rebecca Roylance, Peter Stephens, Olga Oikonomidou, Jeremy Braybrooke, Mark Tuthill, Jacinta Abraham, Matthew Winter, Hannah Bye, Michael Hubank, Heidrun Gevensleben, Ros Cutts, Claire Snowdon, Daniel Rea, David Cameron, Abeer M. Shaaban, Katrina Randle, Sue Martin, Katie Wilkinson, Laura Moretti, Judith M. Bliss, Alistair Ring - The Lancet Oncology 2020 cited by 352

  23. Inavolisib-Based Therapy in PIK3CA -Mutated Advanced Breast Cancer

    Authors: Nicholas C. Turner, Seock‐Ah Im, Cristina Saura, Dejan Juric, Sibylle Loibl, Kevin Kalinsky, Peter Schmid, Sherene Loi, Patrapim Sunpaweravong, Antonino Musolino, Huiping Li, Qingyuan Zhang, Zbigniew Nowecki, Roland Leung, Eirini Thanopoulou, Noopur Shankar, Guiyuan Lei, Thomas J. Stout, Katherine E. Hutchinson, Jennifer L. Schutzman, Chunyan Song, Komal Jhaveri - New England Journal of Medicine 2024 cited by 237

  24. Understanding breast cancer complexity to improve patient outcomes: The St Gallen International Consensus Conference for the Primary Therapy of Individuals with Early Breast Cancer 2023

    Authors: Giuseppe Curigliano, Harold J. Burstein, Michael Gnant, Sibylle Loibl, David Cameron, Meredith M. Regan, Carsten Denkert, Philip Poortmans, William P. Weber, Beat Thürlimann, Stefan Aebi, Meteb Al‐Foheidi, Fabrice André, Mykola Anikusko, R. Badwe, A.V. Barrio, Carlos H. Barrios, Jonas Bergh, Hervé Bonnefoi, Daniela Morales, Sara Y. Brucker, Harold J. Burstein, Carlos Caldas, David Cameron, F. Cardoso, Maria João Cardoso, L.A Carey, Stephen Chia, Charlotte E. Coles, J. Cortes, Giuseppe Curigliano, Jana de Boniface, Suzette Delaloge, A. DeMichele, Carsten Denkert, Gerd Fastner, Florian Fitzal, Prudence A. Francis, H Gamal, Oreste ­Gentilini, Michael Gnant, William J. Gradishar, B. Gulluoglu, Nadia Harbeck, Jörg Heil, Chien Shiun Huang, Jens Huober, Zeping Jiang, Orit Kaidar‐Person, Marleen Kok, Eun‐So Lee, Sherene Loi, S. Loibl, Miguel Martín, Icro Meattini, Monica Morrow, A. H. Partridge, Frédérique Penault‐Llorca, Martine Piccart, Lori J. Pierce, Philip Poortmans, Meredith M. Regan, J. S. Reis-Filho, Isabel T. Rubio, Hope S. Rugo, Emiel J. Rutgers, Cristina Saura, Elżbieta Senkus, Zhi-Ming Shao, Christian F. Singer, Tanja Španič, Beat Thuerlimann, Masakazu Toi, Sara M. Tolaney, Nicholas C. Turner, Andrew Tutt, M.-J. Vrancken Peeters, Toru Watanabe, William P. Weber, Hans Wildiers, B. Xu - Annals of Oncology 2023 cited by 221